Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Other

Boehringer Ingelheim Pharma Gmbh & Co Kg

Zhulin Tan

Nathan K Yee

Jinhua Jeff Song

Chris Hugh Senanayake

Li Feng Zhang

Sonia Rodriguez

Jinghua Xu

Daniel Robert Fandrick

Nizar Haddad

Alan David Swinamer

Xiao-Jun Wang

Fabrice Gallou

Jonathan Timothy Reeves

Nitinchandra D Patel

Bo Qu

Yongda Zhang

Guisheng Li

Jean-Nicolas Desrosiers

Joshua Daniel Sieber

Jun Wang

John R Regan

Pier Francesco Cirillo

Daniel Kuzmich

Hossein Razavi

Weitong Dong

Can Mao

Brian Nicholas Cook

Pingrong Liu

Jon Charles Lorenz

Frank Roschangar

John Lord

Thomas Gabriel Tampone

Darren DiSalvo

Laurence John Nummy

Darren Todd Disalvo

Christian Harcken

Brian Christopher Raudenbush

Thomas Wai-ho Lee

Magnus C Eriksson

Paul S Riska

Pengtao Zhang

Jason Brazzillo

Jolaine Savoie

Joshua D Sieber

Heewon Lee

Jochen Neu

Kanwar Pal Singh Sidhu

Phouvieng Beyer

Jason A Brazzillo

Roger Dinallo

Brian Andrew Walter

Magnus Eriksson

June Wang

Thomas Wai-Ho Lee

The present invention relates to compounds of (II) and an acceptable salt or hydrate thereof method of making same. 

Intermediate compounds and methods

This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. The invention also relates to processes for preparing the novel ligands.

Chiral dihydrobenzooxaphosphole ligands and synthesis thereof

The present invention relates to a compound of formula (I) wherein R, Rand n are as defined herein. The invention also relates to processes for making the compounds of formula (I) and methods of using the compounds of formula (I) as reagents in organic synthesis. 

2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives

Disclosed is a process for preparing substituted anisidines of formula I starting from substituted cyclic hydroxy-ketones II via aromatization through a substituted oxime intermediate IV in which R is C-Calkyl or halogen, and Alk is C-Calkyl. The substituted anisidines of formula I have been found to be useful as intermediates in the preparation of agents for the treatment of hepatitis C viral (HCV) infections. 

Process for preparing substituted anisidines

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.  Also disclosed are methods of making and methods of using same.

Azaindazole compounds as CCR1 receptor antagonists

A process for stereoselective synthesis of compounds of Formula X wherein:

Stereoselective synthesis of certain trifluoromethyl-substituted alcohols

A process for stereoselective synthesis of a compound of Formula (I) wherein R, R, R, R, and Rare as described herein.

Disclosed are methods of making aryl intermediate compounds of the formula (A) which are useful in the production of heteroaryl ureas,Y and P are defined herein below.

Preparation of aryl intermediates

This invention relates to novel processes for preparing heteroaryl-substituted urea compounds of formula (I):which are useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. X, Ar, L, Q andare described herein.

Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents

Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar ,Ar ,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Aromatic heterocyclic compounds as antiinflammatory agents

Growing community of inventors

Danbury, CT, United States of America

Zhulin Tan